Skip to main content

Table 2 Characteristics of included trials

From: Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials

Study

Study design

Setting

Clinical scenario

Primary intervention

Sham infusion

Sample size, n (MSCs/control)

Endpoint

Mean follow-up time points (months)

Withdrawal number, n (%)

Chen et al. 2004 [7]

RCT

Single-center

AMI

PCI

Yes

69 (34/35)

LVEF, LVESV, LVEDV

3, 6

0 (0)

Chullikana et al. 2015 [10]

RCT

Multicenter

AMI

PCI

Yes

20(10/10)

LVEF, Infarct size, Perfusion defect

6, 24

4 (20)

Gao et al. 2013 [28]

RCT

Multicenter

AMI

PCI

Yes

43 (21/22)

LVEF, LVESV, LVEDV, WMSI, LVFS

6, 12, 24

4 (9)

Gao et al. 2015 [27]

RCT

Multicenter

AMI

PCI

Yes

116 (58/58)

LVEF, LVESV, LVEDV, WMSI, LVFS

1, 4, 12, 18

4 (3)

Hare et al. 2009 [29]

RCT

Multicenter

AMI

PCI

Yes

60 (39/21)

LVEF, LVESV, LVEDV

1, 2, 3, 6, 12

0 (0)

Houtgraaf et al. 2012 [12]

RCT

Single-center

AMI

PCI

No

14 (10/4)

LVEF, Infarct size, Perfusion defect

6

1 (7)

Lee et al. 2014 [30]

RCT

Multicenter

AMI

PCI

NR

69 (33/36)

LVEF, LVESV, LVEV, WMSI

1, 2, 6

11 (16)

Wang et al. 2014 [31]

RCT

Single-center

AMI

PCI

Yes

58 (28/30)

LVEF

1, 3, 6

3 (5)

  1. AMI acute myocardial infarction, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVFS left ventricular fractional shortening, MSC mesenchymal stromal cell, NR not reported, PCI percutaneous coronary intervention, RCT randomized controlled trial, WMSI wall motion score index